Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
Recruiting · NCT06650163 · Registry updated 2026-02-05Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, brain cancer, brain disorder, central nervous system cancer, central nervous system disorder, epithelial neoplasm, glioma, meningioma, metastatic malignant neoplasm in the brain, neoplasm, nervous system disorder, neuroepithelial neoplasm, primitive neuroectodermal tumor, tumor of meninges, vascular cancer | Recruiting | Phase 1 | 2026-02-05 | NCT06650163 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Jonsson Comprehensive Cancer Center | 115 |
| National Cancer Institute (NCI) | 3015 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| UCLA / Jonsson Comprehensive Cancer Center | Los Angeles | United States | 126 |